Comparative Evaluation of the Effectiveness of Novel Hyaluronic Acid-Polynucleotide Complex Dermal Filler

Abstract

HA (Hyaluronic acid) filler, the most commonly used dermal filler, causes several side effects. HA-PN (Hyaluronic acid-Polynucleotide), a new composite filler, has excellent biocompatibility and induces tissue regeneration. In this study, we compare the efficacies and safety profiles of these fillers. The characteristics of HA and HA-PN fillers were compared using scanning electron microscopy and rheometry. No morphological difference was noted between the fillers. However, the latter had higher viscosity and elasticity values. The HA-PN filler induced higher cell migration than the HA filler in a wound healing assay. It was also found to stimulate better collagen synthesis in human and mouse fibroblasts. The HA and HA-PN fillers were injected into SKH1 hairless mice to determine changes in their volume for up to 24 weeks. Increased cell migration and collagen synthesis were observed in mice injected with the HA-PN complex filler. Although the safety and durability of the HA and HA-PN fillers were similar, the latter induced a lower transient receptor potential vanilloid 4 expression and caused less stimulation upon injection. In conclusion, HA-PN complex fillers can stimulate fibroblast growth and facilitate volume growth and skin regeneration.

Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy

“…Dermal atrophy owing to irreversible loss of collagen is a hallmark of skin aging 16,17 . Numerous methods have aimed to restore loss of collagen protein in skin, ranging from over the counter and pharmaceutical approaches (antioxidants [18][19][20] , retinoids 21 , peptides 22,23 ) to medical devices (that is, laser therapy 24 and synthetic dermal fillers 25,26 ). However, none of these existing technologies have been able to achieve long-term endogenous collagen replacement to maintain skin strength, firmness and elasticity over time [27][28][29] .…”

Bridging a Century-Old Problem: The Pathophysiology and Molecular Mechanisms of HA Filler-Induced Vascular Occlusion (FIVO)—Implications for Therapeutic Interventions

“…However, the majority of current HA fillers—including Juvéderm ® brands (Allergan Aesthetics, Irvine, CA, USA); Restylane Defyne ® , Refyne ® Kysse ® , and Contour ® (Galderma, Fort Worth, TX, USA); RHA ® 2, 3, 4 and Redensity ® (Revance, Nashville, TN, USA); Revanesse Versa ® (Prollenium, Raleigh, NC, USA); and Belotero Balance ® (Merz, Raleigh, NC, USA)—are considered “monophasic”, representing a continuous, uniform gel matrix that is nonsieved and non-particulate [ 97 , 98 ]. Nevertheless, when dispersed in an aqueous solution, monophasic fillers separate into fragments that also range between 50 and 1200 μm in size [ 99 , 100 ]. Thus, HA fillers are naturally prone to fragmentation and dispersion when exposed to high shear forces during injection, potentially generating embolizable macro- and microparticles.…”

Multi-modulation of immune-inflammatory response using bioactive molecule-integrated PLGA composite for spinal fusion

“…To design an effective biomaterial, we included PDRN in a biomimetic composite because it has excellent pro-angiogenic effects. Most approved forms of PDRN are injectable liquid phases and require other types of processing to introduce them into hard rather than soft tissues, such as leg ulcers, burns, and depressed scars [ 64 , 65 ]. In a previous study, we found that when administered in the body, PDRN selectively exerts anti-inflammatory effects, cell proliferation, and angiogenic effects at injured sites through its adenosine A2a receptor agonistic effect and salvage pathway [ 19 , 20 ].…”